Clinical Trial Update: Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating low-dose immunotherapy in locally advanced MMR-deficient colorectal cancer (MSI-H).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Snippet

Sponsor: Blokhin's Russian Cancer Research Center | Conditions: Colorectal Cancer (MSI-H), Colorectal Cancer (CRC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING